Miniaturized Forced Degradation of Therapeutic Proteins and ADCs by Agitation-Induced Aggregation Using Orbital Shaking of Microplates.

Antibody drug conjugate(s) (ADC) Forced conditions Formulation High throughput technology(s) Interfacial stress Mechanical stress Monoclonal antibody(s) Physical stability Protein aggregation

Journal

Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R

Informations de publication

Date de publication:
05 2022
Historique:
received: 01 06 2021
revised: 19 09 2021
accepted: 19 09 2021
pubmed: 27 9 2021
medline: 21 4 2022
entrez: 26 9 2021
Statut: ppublish

Résumé

Microplate-based formulation screening is a powerful approach to identify stabilizing excipients for therapeutic proteins while reducing material requirements. However, this approach is sometimes not representative of studies conducted in relevant container closures. The present study aimed to identify critical parameters for a microplate-based orbital shaking method to screen biotherapeutic formulations by agitation-induced aggregation. For this purpose, an in-depth methodological study was conducted using different shakers, microplates, and plate seals. Aggregation was monitored by size exclusion chromatography, turbidity, and backgrounded membrane imaging. Both shaker quality and liquid-seal contact had substantial impacts on aggregation during shaking and resulted in non-uniform sample treatment when parameters were not suitably selected. The well volume to fill volume ratio (V

Identifiants

pubmed: 34563536
pii: S0022-3549(21)00497-4
doi: 10.1016/j.xphs.2021.09.027
pii:
doi:

Substances chimiques

Excipients 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1401-1413

Informations de copyright

Copyright © 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

Auteurs

Florian Johann (F)

Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Department of Pharmaceutics, Freeze Drying Focus Group (FDFG), Cauerstraße 4, 91058 Erlangen, Germany; Merck KGaA, Department of Pharmaceutical Technologies, Frankfurter Straße 250, 64293 Darmstadt, Germany.

Steffen Wöll (S)

Merck KGaA, Department of Pharmaceutical Technologies, Frankfurter Straße 250, 64293 Darmstadt, Germany.

Matthias Winzer (M)

Merck KGaA, Department of Pharmaceutical Technologies, Frankfurter Straße 250, 64293 Darmstadt, Germany.

Jared Snell (J)

EMD Serono Research and Development Institute, Department of Pharmaceutical Technologies, 45A Middlesex Turnpike, Billerica, MA 01821, USA.

Bernhard Valldorf (B)

Merck KGaA, Department of Pharmaceutical Technologies, Frankfurter Straße 250, 64293 Darmstadt, Germany.

Henning Gieseler (H)

Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Department of Pharmaceutics, Freeze Drying Focus Group (FDFG), Cauerstraße 4, 91058 Erlangen, Germany; GILYOS GmbH, Friedrich-Bergius-Ring 15, 97076 Würzburg, Germany. Electronic address: info@gilyos.com.

Articles similaires

Measurement of α-synuclein as protein cargo in plasma extracellular vesicles.

Tal Gilboa, Dmitry Ter-Ovanesyan, Shih-Chin Wang et al.
1.00
alpha-Synuclein Extracellular Vesicles Humans Phosphorylation Parkinson Disease
Flurbiprofen Tablets Administration, Oral Drug Compounding Solubility
Powders Machine Learning Wettability Particle Size Viscosity
Tablets Silicon Dioxide Excipients Porosity Drug Compounding

Classifications MeSH